Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga

Potential to mix up omicron booster with conventional vaccine raises concerns

Experts are voicing concerns about the potential for vaccine providers to mix up the omicron booster vial with those used for conventional vaccines.

Los Angeles Times

ALS drug gets rare second review at high-stakes FDA meeting

The Food and Drug Administration is holding an unusual second meeting to review a closely watched drug for the illness known as Lou Gehrig’s disease

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy.

Benzinga

E-Cigarette Maker To Pay Over $430M To Settle Multi-State Vaping Inquiry, Cannabis Investors Need To Pay Attention

E-cigarette producer Juul Labs agreed to pay $438.5 million to 34 states and territories to sort out a two-year bipartisan investigation into its marketing and sales practices.

Benzinga

ACOGF: Bioequivalence Complete

By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT

Benzinga

Stopgap funding bill set to dominate September agenda

Lawmakers return to Washington this month to wrestle with a White House request for $47.1 billion in emergency supplemental funds and the need to pass a stopgap spending bill to avoid a partial government shutdown starting Oct. 1.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Juul reaches $439 million settlement over marketing to children

Juul Labs Inc. reached an agreement in principle to pay $438.5 million to 33 states to resolve a two-year bipartisan probe into the e-cigarette manufacturer’s marketing and sales practices, particularly claims that it marketed addictive nicotine products to children.

Tribune News Service

Juul will pay nearly $440 million to settle states' investigation into teen vaping

The electronic cigarette maker has agreed to settle a two-year investigation by 33 states and Puerto Rico into the marketing of its vaping products, which have been blamed for a surge in teen vaping.

WEKU

Juul to pay nearly $440M to settle states' teen vaping probe

Electronic cigarette maker Juul Labs will pay nearly $440 million to settle a multi-state investigation into its vaping products, which have long been blamed for sparking a national surge in teen vaping

The Independent UK

Stopgap funding bill set to dominate September agenda - Roll Call

Lawmakers will wrestle with a White House request for $47.1 billion in emergency funds and the need to avert a partial government shutdown.

Roll Call

Unions call on Truss to crack down on sexual harassment in Westminster

Prospect and FDA say new leadership brings a fresh opportunity to restore confidence that Parliament is a safe place to work.

The Independent UK

NERV Stock Is on the Move, but Is It a Buy?

Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash burn. Despite its limited earnings growth prospects, the stock has gained more than 260% over the past month because the company submitted an NDA for…

StockNews.com

The man who breeds tens of thousands of leeches for the NHS from a tiny Welsh farm

Carl Peters-Bond, from Biopharm Leeches in Hendy, is one of just two FDA registered leech farmers in the world

Wales Online

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Food expiration dates are confusing

A food safety researcher explains another way to know what’s too old to eat

The Independent UK

FDA still skeptical of ALS drug ahead of high-stakes meeting

The U.S. Food and Drug Administration has posted another negative review of a closely watched drug for the deadly neurodegenerative disease ALS

StockNews.com

3 Stocks With Decades of Dividend Payments

Concerns over high inflation, the Fed’s hawkish stance to control it, and an economic slowdown have led to immense stock market volatility. Therefore, it could be wise to invest in stocks with decades of dividend-paying history, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Becton, Dickinson and Company (BDX),…

The Independent UK

Does Paxlovid cause Covid rebound?

US president and first lady have both reported relapses after using drug to treat coronavirus

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

EXPLAINER: Should you get a new COVID booster? If so, when?

New COVID-19 boosters targeting today’s most common omicron strains should begin arriving within days

Reason

Where Is the Republican Plan To Reform Public Health?

The GOP has understandably cast Anthony Fauci as a villain, but there are few plans to overhaul public health bureaucracies.

Axios

"Game-changer" Paxlovid turns into pandemic enigma

Paxlovid goes from COVID game-changer to pandemic enigma

Los Angeles Times

CDC advisers endorse booster shots that target omicron for Americans 12 and up

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

WEKU

CDC recommends new booster shots to fight omicron

CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.

StockNews.com

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

1 … 181 182 183 184

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

346 stories

ABT

323 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.